Fredun Pharmaceuticals Limited, a pharmaceutical company based in Maharashtra, has reported a significant increase in its financial performance for the quarter ended September 30, 2025. The company's unaudited financial results, approved by the Board of Directors on November 8, 2025, reveal substantial growth in both revenue and profitability.

Financial Highlights

The company's performance shows a remarkable improvement across key financial metrics:

• Net Profit: Jumped by 128% to ₹9.73 crore, compared to ₹4.27 crore in the same quarter last year.
• Revenue: Increased by 45% to ₹149.59 crore from ₹102.99 crore year-on-year.
• Earnings Per Share (EPS): More than doubled to ₹20.61 from ₹9.05 in the corresponding quarter.

Half-Year Performance

For the half-year period, Fredun Pharmaceuticals reported a net profit of ₹16.50 crore, up from ₹8.40 crore in the previous comparable period, marking a significant improvement in the company's financial health.

Company Overview

Fredun Pharmaceuticals Limited operates in the pharmaceutical and healthcare segment. The company's manufacturing facilities are located in Palghar, Maharashtra, positioning it strategically in one of India's key pharmaceutical hubs.

Board Meeting and Compliance

The Board of Directors convened on November 8, 2025, to approve these unaudited financial results. The meeting, which started at 4:00 p.m., concluded at 10:30 p.m., indicating a thorough review of the company's performance.

In compliance with SEBI regulations, the company had closed its trading window for insiders from October 1, 2025, until 48 hours after the declaration of the financial results, ensuring fair trading practices.

Auditor's Review

R.H. Nisar & Co., the statutory auditors, conducted a limited review of the consolidated unaudited financial results. Their review, performed in accordance with the Standard on Review Engagements (SRE) 2410, found no material misstatements in the financial information provided by the company.

The strong financial performance of Fredun Pharmaceuticals Limited in Q2 FY2026 reflects the company's robust growth trajectory in the pharmaceutical sector. These results demonstrate significant improvements in profitability and revenue amidst the current economic environment.

Fredun Pharmaceuticals Limited (FPL), a leading pharmaceutical formulation manufacturer in India, has made a strategic move into the burgeoning pet care industry by acquiring Wagr.ai, a prominent pet tech platform. This acquisition marks FPL's entry into India's pet care sector, which is projected to reach $6 billion by 2030.

Key Highlights of the Acquisition

• Asset Acquisition: FPL has acquired all assets of Wagr, including its technology platform, user base, patented pet fitness tracking technology, and established veterinary network.
• Market Position: The acquisition positions FPL at the forefront of India's rapidly growing pet care industry.
• Neutral Marketplace: FPL plans to relaunch Wagr.ai as India's first truly neutral online marketplace for pet products and services in Q4 FY 2025-26.

Strategic Rationale and Synergies

The acquisition brings together FPL's expertise in pet nutrition with Wagr's cutting-edge technology, creating a comprehensive ecosystem for pet care in India. Key synergies include:

1. Diverse Product Offering: FPL's specialization in functional food and prescription food categories complements Wagr's technology platform.
2. Comprehensive Support System: The integrated platform will offer multiple support channels for pet parents, including:
   • On-demand telemedicine services
   • Pan-India doctor network
   • AI-powered pet care chatbot
3. Innovative Technology: FPL plans to reintroduce Wagr's patented fitness tracking technology for pets in FY 2026-27, offering real-time health monitoring for pets.

Transaction Structure and Ownership

The acquisition is structured as a zero-cash transaction, with Wagr's investors and founding team joining FPL as equity partners. The new ownership structure is as follows:

Market Opportunity and Future Outlook

India's pet care industry is experiencing rapid growth, with a projected CAGR of 22% from 2021 to 2030. The market encompasses various segments:

Fredun Medhora, MD of Fredun Pharmaceuticals Limited, stated, "FPL's long-term vision is that every pet in India should be using a FPL product or service. This strategic acquisition represents a transformative moment for the Indian pet care industry."

The combined platform brings impressive operational capabilities, including a user base of 140,000+ registered pet parents, 16,000+ transactions, and relationships with 70+ pet care product brands.

This strategic move by Fredun Pharmaceuticals demonstrates the company's commitment to diversifying its portfolio and capitalizing on the growing pet care market in India. The integration of Wagr's technology with FPL's expertise in pet nutrition creates a unique value proposition in the Indian pet care landscape, potentially reshaping the industry's future.

As the pet care market in India continues to expand, this acquisition positions Fredun Pharmaceuticals to capture a significant share of this growth, leveraging technology and innovation to meet the evolving needs of pet parents across the country.